Dr Wan Fariza Binti Wan Jamaludin

Certification & Qualification

• MBBS (London), MRCP (UK), AM (Mal.), FRCP (UK) 
  
• Bachelor of Medicine and Bachelor of Surgery (MBBS), St. George's Hospital Medical School, University of London, England.
  
• Member of the Royal College of Physicians, United Kingdom (MRCP UK)
  
• Member of the Academy of Medicine (Malaysia)
  
• Fellowship of the Royal College of Physicians, United Kingdom (FRCP UK)
  
• Fellowship of Clinical Haematology (MSH)
  
• Specialist Registrar Haematology, Royal Devon & Exeter Hospital, England (NHS UK) 2007-2008.
  
• Specialist Registrar Haematology, Musgrove Park Hospital, Somerset, England (NHS UK) 2009.
  
• Senior Lecturer Haematology, Universiti Teknologi MARA Selayang, Malaysia 2010-2012.
  
• Deputy Head, Cell Therapy Centre, (Bone Marrow Transplantation), Pusat Perubatan Universiti Kebangsaan Malaysia, 2018-2020.
  
• Associate Professor, Consultant Physician and Clinical Haematologist, Pusat Perubatan Universiti Kebangsaan Malaysia, 2012-2022.
  
• Adjunct Professor, Taylor's University School of Medicine, Malaysia 2023.
  
• Malaysian Society of Haematology (Member)
  
• Malaysian Society of Transplantation (Member)
  
• University award Q1 Research Publication: Dengue infection associated hemophagocytic syndrome: Therapeutic interventions and outcome (2015).
  
• National award Best Oral & Poster Presentation: The Value of 18-FDG PETCT Scan Versus Bone Marrow Biopsy in Detecting and Predicting the Outcomes of Patient with Bone Marrow Involvement in 18F-FDG Avid Lymphoma (2017).
  
• Good Citizen Award for volunteering health programs in PPR Bukit Jalil - Persatuan Zhong Yuan Puchong Selatan (2017).
  
• University award for research grant: The Value of PET/CT scan in Determining Remission Status in Lymphoma Patients Involving the Head & Neck Region (2019).
  
• University award for external research grant with Monash University: The Asia Pacific Myeloma and Related Diseases Registry (2020).
  
• National award Best Oral & Poster Presentation: Clinical Outcomes of Relapsed or Refractory Diffuse Large B Cell Lymphoma - A Multicenter Real-World Study in Malaysia (2022).